Zhenlin Hou

1.7k total citations · 2 hit papers
22 papers, 1.2k citations indexed

About

Zhenlin Hou is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Zhenlin Hou has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 4 papers in Surgery. Recurrent topics in Zhenlin Hou's work include Epigenetics and DNA Methylation (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Colorectal Cancer Screening and Detection (4 papers). Zhenlin Hou is often cited by papers focused on Epigenetics and DNA Methylation (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Colorectal Cancer Screening and Detection (4 papers). Zhenlin Hou collaborates with scholars based in China, United States and Taiwan. Zhenlin Hou's co-authors include Junbo Hu, Guihua Wang, Xuelai Luo, Fuqing Hu, Jingqin Lan, Da Song, Feng Xu, Lu Liu, Xianglin Yuan and Li Sun and has published in prestigious journals such as Journal of Clinical Oncology, Nature Cell Biology and Cancer Research.

In The Last Decade

Zhenlin Hou

20 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer

2018 515 citations Jingqin Lan, Li Sun et al. Cancer Research profile →
Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

2023 240 citations Weihao Li, Chi Zhou et al. Autophagy profile →

Peers

Countries citing papers authored by Zhenlin Hou

Since Specialization

Citations

This map shows the geographic impact of Zhenlin Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenlin Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenlin Hou more than expected).

Fields of papers citing papers by Zhenlin Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenlin Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenlin Hou. The network helps show where Zhenlin Hou may publish in the future.

Co-authorship network of co-authors of Zhenlin Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenlin Hou. A scholar is included among the top collaborators of Zhenlin Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenlin Hou. Zhenlin Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative outcomes and prognosis in patients with ureteral upper tract urothelial carcinoma undergoing segmental ureterectomy versus radical nephroureterectomy: a multicenter cohort study 2025 ·International Journal of Surgery ·(unknown), (unknown), Zhenlin Hou, Xiaochen Du, Mengxin Chen, (unknown), Yi‐Hao Chen, Minjie Wang, Ruixue Dai, (unknown), Zixuan Li, (unknown), Xuesong Li, (unknown)	0
2	Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study 2025 ·npj Precision Oncology ·Zhenlin Hou, (unknown), Weiwei Xiao, Qiaoqi Sui, Kai Han, Binyi Xiao, Yuan Li, Wei-Jian Mei, Jiehai Yu, (unknown), Qichen Chen, (unknown), Dandan Li, Xiaoshi Zhang, Qiaoxuan Wang, Zhizhong Pan, (unknown), Peirong Ding	1
3	The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study 2024 ·BMC Cancer ·(unknown), Jinghua Tang, (unknown), Jiang Wu, Yuan Li, Ling-Heng Kong, Kai Han, Zhenlin Hou, Chenzhi Zhang, (unknown), Linjie Zhang, Qiaoqi Sui, Binyi Xiao, Wei-Jian Mei, Jiehai Yu, (unknown), Zhizhong Pan, Peirong Ding	2
4	A log odds of positive lymph nodes-based predictive model effectively forecasts prognosis and guides postoperative adjuvant chemotherapy duration in stage III colon cancer: a multi-center retrospective cohort study 2024 ·BMC Cancer ·W. Zhang, Zhenlin Hou, Linjie Zhang, (unknown), Weifeng Wang, Xiaojun Wu, Dongbo Xu, (unknown), Jianxun Chen, Jianhong Peng	1
5	Serum biomarkers REG1A and REG3A combined with the traditional CEA represent a novel nomogram for the screening and risk stratification of colorectal cancer 2024 ·Clinical & Translational Oncology ·Long Yu, Hao Wang, Fulong Wang, Jian Guo, Binyi Xiao, Zhenlin Hou, Zhenhai Lu, Zhizhong Pan, (unknown), (unknown), Desen Wan, Bo Lin, Qingjian Ou, Yujing Fang	2
6	Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer breakdown → 2023 ·Autophagy ·Weihao Li, Chi Zhou, Long Yu, Zhenlin Hou, Huashan Liu, Ling-Heng Kong, Yanbo Xu, Jiahua He, Lan Jin, Qingjian Ou, Yujing Fang, Zhenhai Lu, Xiaojun Wu, Zhizhong Pan, Jianhong Peng, Junzhong Lin	240
7	PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer. 2023 ·Journal of Clinical Oncology ·Zhenlin Hou, Jiang Wu, Jinghua Tang, Binyi Xiao, Yuan Li, Dandan Li, Xiaoshi Zhang, Zhizhong Pan, Peirong Ding	2
8	DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer 2022 ·Clinical & Translational Oncology ·Yuan Li, (unknown), Ling-Heng Kong, Jiang Wu, Jinghua Tang, Kai Han, Zhenlin Hou, Chenzhi Zhang, (unknown), Linjie Zhang, Qiaoqi Sui, Binyi Xiao, Wei-Jian Mei, Yanbo Xu, Jiehai Yu, (unknown), Zhizhong Pan, Peirong Ding	1
9	RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2 2022 ·Oncogene ·Yaqi Chen, (unknown), (unknown), Long Yu, Chongchong Zhao, Haiteng Deng, Qingjian Ou, (unknown), Junbo Hu, Zhenlin Hou	21
10	Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer 2022 ·Cancer Medicine ·Junzhong Lin, Hui Sun, (unknown), (unknown), Zhenhai Lu, Zhizhong Pan, Zhenlin Hou, Jianhong Peng	4
11	[Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer]. 2022 ·PubMed ·(unknown), (unknown), Yuxiang Deng, Zhenlin Hou, (unknown), Junzhong Lin, Zhi-Zhong Pan, Zhen Lu, Jianhong Peng	0
12	Author Correction: SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis 2021 ·Nature Cell Biology ·Guihua Wang, Jie Long, Yuan Gao, Weina Zhang, Fei Han, Chuan Xu, Li Sun, (unknown), Jingqin Lan, Zhenlin Hou, Zhen Cai, Guoxiang Jin, (unknown), Yu-Hui Wang, Junbo Hu, Tsai‐Yu Chen, Hongyu Li, Min Gyu Lee, Hui‐Kuan Lin	4
13	TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability 2021 ·Cell Death and Disease ·Sha Zhou, Jianhong Peng, (unknown), (unknown), Yujing Fang, Qingjian Ou, (unknown), Mengzhong Liu, Zhizhong Pan, Zhenlin Hou	43
14	Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer 2020 ·Cancer Letters ·Zhenlin Hou, Li Sun, Feng Xu, Fuqing Hu, Jingqin Lan, Da Song, Yongdong Feng, Jing Wang, Xuelai Luo, Junbo Hu, Guihua Wang	29
15	SIX4 promotes metastasis through STAT3 activation in breast cancer. 2020 ·PubMed ·Xuling Sun, Jin Ma, (unknown), Zhenlin Hou, Xuelai Luo, Guihua Wang, Jing Wang, Junbo Hu, Zhixin Cao	25
16	The autophagy-independent role of BECN1 in colorectal cancer metastasis through regulating STAT3 signaling pathway activation 2020 ·Cell Death and Disease ·Fuqing Hu, Li Geng, Changsheng Huang, Zhenlin Hou, Xi Yang, Xuelai Luo, Yongdong Feng, Guihua Wang, Junbo Hu, Zhixin Cao	52
17	SIX4 activates Akt and promotes tumor angiogenesis 2019 ·Experimental Cell Research ·Xuling Sun, Fuqing Hu, Zhenlin Hou, (unknown), Jingqin Lan, Xuelai Luo, Guihua Wang, Junbo Hu, Zhixin Cao	22
18	SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis 2019 ·Nature Cell Biology ·Guihua Wang, Jie Long, Yuan Gao, Weina Zhang, Fei Han, Chuan Xu, Li Sun, (unknown), Jingqin Lan, Zhenlin Hou, Zhen Cai, Guoxiang Jin, (unknown), Yu-Hui Wang, Junbo Hu, Tsai‐Yu Chen, Hongyu Li, Min Gyu Lee, Hui‐Kuan Lin	143
19	M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer breakdown → 2018 ·Cancer Research ·Jingqin Lan, Li Sun, Feng Xu, Lu Liu, Fuqing Hu, Da Song, Zhenlin Hou, Wei Wu, Xuelai Luo, Jing Wang, Xianglin Yuan, Junbo Hu, Guihua Wang	515
20	TRIB2 functions as novel oncogene in colorectal cancer by blocking cellular senescence through AP4/p21 signaling 2018 ·Molecular Cancer ·Zhenlin Hou, (unknown), Xuling Sun, Fuqing Hu, (unknown), Xuelai Luo, Guihua Wang, Junbo Hu, Li Sun	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact